Grimaldi P A
Inserm U470, Centre de Biochimie, Parc Valrose, 06108 Nice, France.
Biochem Soc Trans. 2003 Dec;31(Pt 6):1130-2. doi: 10.1042/bst0311130.
PPARdelta (peroxisome proliferator-activated receptor delta)-specific agonists decrease plasma lipids and insulinaemia in obese animals. As skeletal muscle is one of the major organs for fatty acid catabolism, we have investigated the roles of the nuclear receptor in the control of muscle development and lipid metabolism, by using two approaches. We have used C(2)C(12) myotubes in which the PPARdelta activity was altered by overexpression of either native or dominant-negative (DN) mutant forms of PPARdelta. Treatment of C(2)C(12) cells by specific PPARdelta agonists promotes expression of genes for proteins of fatty acid catabolism and increases fatty acid oxidation. These responses were increased in C(2)C(12)-PPARdelta cells and impaired in C(2)C(12)-PPARdeltaDN cells. We also constructed animal models with muscle-specific expression of PPARdelta (Cre/Lox approach). The effects of muscle-specific alteration of PPARdelta activity were studied on muscle development and metabolism as well as on body fat mass. These experiments indicated that PPARdelta plays a crucial role in myofibre typing determination and regulation of muscle oxidative capabilities, and that muscle-specific overexpression of the nuclear receptor leads to reduction of adipocyte size and body fat mass. These data strongly suggest that PPARdelta controls fatty acid catabolism in muscle and that its activation by synthetic agonists could prevent or correct obesity and type 2 diabetes.